Dr. Kennedy is the Co-Founder and Chief Scientific Officer of PinkDx, a molecular diagnostic company focused on women’s healthcare. Prior to co-founding PinkDx, she was Chief Scientific Officer and Chief Medical Officer of Veracyte, joining in 2008 as a member of the founding team. While at Veracyte, Dr. Kennedy led the development and commercialization of eight genomic tests that changed the standard of patient care, using machine learning to develop tests that answer critical clinical questions. Prior to Veracyte, Dr. Kennedy was Senior Director of Genomics Collaborations at Affymetrix, Inc. and led the transition of a novel microarray-based genotyping method from early research through product development and successful commercialization. Previously, Dr. Kennedy was a scientific leader for the colon cancer and breast cancer gene discovery efforts at Chiron Corporation. Before that, she was a scientist at Millennium Pharmaceuticals, where she implemented genetic approaches to study diabetes. In addition to joining as a member of the Board of Directors at Encodia, Inc in 2023, she has been a member of the Board of Directors at Acuamark, Inc. since 2021 and Astarte Medical since 2018. Previously she was a member of the Medical Advisory Board at Intervenn, Inc. She is an advisor for the UCSF Catalyst program, a translational accelerator focused on advancing discoveries with clinical impact and commercial potential. In 2020 Dr. Kennedy was named one of the Bay Area’s 100 Most Influential Women in Business by the San Francisco Business Times.

Dr. Kennedy holds a Ph.D. degree in Biochemistry and completed postdoctoral training at the University of California at San Francisco in the Biochemistry Department and Hormone Research Institute. Dr. Kennedy has published more than 70 articles in peer-reviewed scientific journals and is a co-inventor on more than 30 patents.